Mike is best known as a patent litigator, advising clients in a variety of sectors, but in particular the biotechnology, pharmaceutical and chemical sectors. Mike heads up the firm’s life sciences litigation practice.
Mike is considered one of the UK’s leading experts in matters concerning Supplementary Protection Certificates (“SPCs”), a highly specialised area of patent law in which there are relatively few practitioners.
He masterminded victory for AZ in the high-profile and high value Astex Therapeutics v AstraZeneca litigation, and for Pfizer in the GSK v Pfizer litigation. He was involved in the 6 patent Pfizer v GSK case and led the Eli Lilly v Genentech litigation. Together with Graham Burnett-Hall, he represented Roche in its patent litigation against Takeda. He is also leading the current UK patent litigation for Pfizer (Wyeth) against MSD concerning one of Pfizer’s most important pneumococcal vaccines, Prevenar 13. That case came on for trial in June/July 2020 and was one of the first fully remote patent trials to be heard in the UK.
Mike has a long standing list of high profile biopharmaceutical clients, including Daiichi Sankyo, Genentech, Roche, Pfizer, AstraZeneca, Abbvie, MedImmune, Curis, Chugai and Amgen.